Literature DB >> 21206005

Expression of HER2 in colorectal cancer does not correlate with prognosis.

Wiesław Janusz Kruszewski1, Robert Rzepko, Maciej Ciesielski, Jarosław Szefel, Jacek Zieliński, Mariusz Szajewski, Wojciech Jasiński, Krzysztof Kawecki, Janusz Wojtacki.   

Abstract

Estimation of HER2 membranous expression is routinely used in breast and gastric cancers, as both a prognostic and a predictive factor. To date there is no evidence for similar application of HER2 expression in colorectal cancer (CRC) cells. In CRC, HER2 is sometimes overexpressed in the cell membrane and very often in the cytoplasm. This study was conducted to determine possible correlations between both membranous and cytoplasmatic expression of HER2 in CRC cells and the outcome of the disease. The prognostic significance of combined staining intensity in the cell membrane and cytoplasm in the entire CRC cell was also investigated. HER2 expression in resectable colorectal adenocarcinoma cells was evaluated by immunohistochemistry in specimens taken from 202 patients. The percentage of cancer cells with membranous or cytoplasmatic reactions and the staining intensity of the reaction in the whole cell were recorded. A membranous reaction was present in 27% of cases, and cytoplasmatic reaction in 66% of cases. The total staining intensity in the entire cell was evaluated as moderate (2+) in 32% of cases and strong (3+) staining in 15%. There was no correlation found between either membranous or cytoplasmatic HER2 expression and survival. Furthermore combined staining intensity did not provide any prognostic information. We conclude that HER2 expression in CRC does not correlate with prognosis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21206005      PMCID: PMC3835377          DOI: 10.3233/DMA-2010-0742

Source DB:  PubMed          Journal:  Dis Markers        ISSN: 0278-0240            Impact factor:   3.434


  23 in total

1.  Expression of EGFR, HER2, phosphorylated ERK and phosphorylated MEK in colonic neoplasms of familial adenomatous polyposis patients.

Authors:  Jayson Wang; James Hollingshead; Nabil El-Masry; Donna Horncastle; Ian Talbot; Ian Tomlinson; Malcolm R Alison; Mona El-Bahrawy
Journal:  J Gastrointest Cancer       Date:  2012-09

2.  Organ Specific Tumor Markers: What's New?

Authors:  Kannan Vaidyanathan; D M Vasudevan
Journal:  Indian J Clin Biochem       Date:  2011-11-08

3.  Lgr5 over-expression is positively related to the tumor progression and HER2 expression in stage pTNM IV colorectal cancer.

Authors:  Feng-Juan Gao; Jie-Yu Chen; Hong-Yan Wu; Jiong Shi; Ming Chen; Xiang-Shan Fan; Qin Huang
Journal:  Int J Clin Exp Pathol       Date:  2014-03-15

4.  Assessment of a HER2 scoring system for colorectal cancer: results from a validation study.

Authors:  Emanuele Valtorta; Cosimo Martino; Andrea Sartore-Bianchi; Frédérique Penaullt-Llorca; Giuseppe Viale; Mauro Risio; Massimo Rugge; Walter Grigioni; Katia Bencardino; Sara Lonardi; Vittorina Zagonel; Francesco Leone; Johannes Noe; Fortunato Ciardiello; Carmine Pinto; Roberto Labianca; Stefania Mosconi; Claudio Graiff; Giuseppe Aprile; Barbara Frau; Carlo Garufi; Fotios Loupakis; Patrizia Racca; Giuseppe Tonini; Calogero Lauricella; Silvio Veronese; Mauro Truini; Salvatore Siena; Silvia Marsoni; Marcello Gambacorta
Journal:  Mod Pathol       Date:  2015-10-09       Impact factor: 7.842

5.  Variability in HER2 expression between primary colorectal cancer and corresponding metastases.

Authors:  Lina Shan; Yiming Lv; Bingjun Bai; Xuefeng Huang; Hongbo Zhu
Journal:  J Cancer Res Clin Oncol       Date:  2018-09-10       Impact factor: 4.553

6.  Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites.

Authors:  Wafik S El-Deiry; Namrata Vijayvergia; Joanne Xiu; Angelique Scicchitano; Bora Lim; Nelson S Yee; Harold A Harvey; Zoran Gatalica; Sandeep Reddy
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

7.  Molecular Oncology in Management of Colorectal Cancer.

Authors:  Ramraj Nagendra Gupta Vemala; Sanjeev Vasudev Katti; Bhawna Sirohi; Divya Manikandan; Govind Nandakumar
Journal:  Indian J Surg Oncol       Date:  2021-03-16

8.  HER2 positivity as a biomarker for poor prognosis and unresponsiveness to anti-EGFR therapy in colorectal cancer.

Authors:  Wenbai Huang; Yijiao Chen; Wenju Chang; Li Ren; Wentao Tang; Peng Zheng; Qi Wu; Tianyu Liu; Yu Liu; Ye Wei; Jianmin Xu
Journal:  J Cancer Res Clin Oncol       Date:  2021-06-22       Impact factor: 4.553

Review 9.  Beyond RAS and BRAF: HER2, a New Actionable Oncotarget in Advanced Colorectal Cancer.

Authors:  Chiara Guarini; Teresa Grassi; Gaetano Pezzicoli; Camillo Porta
Journal:  Int J Mol Sci       Date:  2021-06-24       Impact factor: 5.923

10.  Cytoplasmic Overexpression of HER2: a Key Factor in Colorectal Cancer.

Authors:  Erik J Blok; Peter Jk Kuppen; Jeroen Em van Leeuwen; Cornelis Fm Sier
Journal:  Clin Med Insights Oncol       Date:  2013-02-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.